International Journal of Hematology

, Volume 83, Issue 2, pp 96–102 | Cite as

New Insight into the Molecular Basis of Hemophilia A

Article

Abstract

Since publication of the sequence of the factor VIII gene (F8) in 1984, a large number of mutations that cause hemophilia A (HA) have been identified.With the technical advances associated with mutation screenings, it is now possible to identify a putative F8 sequence alteration in the great majority of HA patients. The mutation spectrum includes 2 inversion hot spots (intron 1 and intron 22 inversions) mediated by intrachromosomal recombination between 2 copies of long inverted repeats, one of which lies within the F8 gene whereas the other is extragenic. Point mutations are distributed over all of the exons, and deletions or insertions of different sizes and mutations affecting splice sites account for the rest of the known mutations. In a small number of cases, however, we are unable to find any disease-determining DNA changes in the coding regions of the F8 gene. This fact points to possibilities of unknown gene rearrangements that disrupt the F8 gene or mutations in other genes that play a role in the processing/secretion of the factor VIII protein. Moreover, the proof of an absence of F8 messenger RNA (mRNA) in one patient points to either a defect in the expression of F8 mRNA or its rapid degradation, which may represent a novel mechanism leading to HA.

Key words

Factor VIII Hemophilia A Mutations mRNA Expression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McGlynn LK, Mueller CR, Begbie M, Notley CR, Lillicrap D.Role of the liver-enriched transcription factor hepatocyte nuclear factor 1 in transcriptional regulation of the factor V111 gene. Mol Cell Biol. 1996;16:1936–1945.CrossRefGoogle Scholar
  2. 2.
    Morris JA, Dorner AJ, Edwards CA, Hendershot LM, Kaufman RJ.Immunoglobulin binding protein (BiP) function is required to protect cells from endoplasmic reticulum stress but is not required for the secretion of selective proteins. J Biol Chem. 1997;272:4327–4334.CrossRefGoogle Scholar
  3. 3.
    Pipe SW, Morris JA, Shah J, Kaufman RJ. Differential interaction of coagulation factor VIII and factor V with protein chaperones calnexin and calreticulin. J Biol Chem. 1998;273:8537–8544.CrossRefGoogle Scholar
  4. 4.
    Nichols WC, Seligsohn U, Zivelin A, et al. Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factorsV and VIII. Cell. 1998;93:61–70.CrossRefGoogle Scholar
  5. 5.
    Zhang B, Cunningham MA, Nichols WC, et al. Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet. 2003;34:220–225.CrossRefGoogle Scholar
  6. 6.
    Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood. 1989;74:1591–1599.PubMedGoogle Scholar
  7. 7.
    Gaucher C, Mercier B, Jorieux S, Oufkir D, Mazurier C. Identification of two point mutations in the von Willebrand factor gene of three families with the‘Normandy’ variant of von Willebrand disease. Br J Haematol. 1991;78:506–514.CrossRefGoogle Scholar
  8. 8.
    Hilbert L, d’Oiron R, Fressinaud E, Meyer D, Mazurier C, and the INSERM Network on Molecular Abnormalities in von Willebrand Disease. First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene. J Thromb Haemost. 2004;2:2271–2273.CrossRefGoogle Scholar
  9. 9.
    Schneppenheim R, Lenk H, Obser T, et al. Recombinant expression of mutations causing von Willebrand disease type Normandy: characterization of a combined defect of factor VIII binding and multimerization. Thromb Haemost. 2004;92:36–41.PubMedGoogle Scholar
  10. 10.
    Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature. 1984;312:326–330.CrossRefGoogle Scholar
  11. 11.
    Naylor JA, Buck D, Green P, Williamson H, Bentley D, Giannelli F. Investigation of the factor VIII intron 22 repeated region (int22h) and the associated inversion junctions. Hum Mol Genet. 1995;4:1217–1224.CrossRefGoogle Scholar
  12. 12.
    Antonarakis SE, Rossiter JP, Young M, et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood. 1995;86:2206–2212.PubMedGoogle Scholar
  13. 13.
    Levinson B, Kenwrick S, Lakich D, Hammonds G Jr, Gitschier J. A transcribed gene in an intron of the human factor VIII gene. Genomics. 1990;7:1–11.CrossRefGoogle Scholar
  14. 14.
    Levinson B, Kenwrick S, Gamel P, Fisher K, Gitschier J. Evidence for a third transcript from the human factor VIII gene. Genomics. 1992;14:585–589.CrossRefGoogle Scholar
  15. 15.
    Kemball-Cook G, Tuddenham EG, Wacey AI. The Factor VIII Structure and Mutation Resource Site: HAMSTeRS version 4. Nucleic Acids Res. 1998;26:216–219.CrossRefGoogle Scholar
  16. 16.
    Peters MF, Ross CA. Isolation of a 40-kDa huntingtin-associated protein. J Biol Chem. 2001;276:3188–3194.CrossRefGoogle Scholar
  17. 17.
    Hollestelle MJ,Thinnes T, Crain K, et al.. Tissue distribution of factor VIII gene expression in vivo: a closer look. Thromb Haemost. 2001;86:855–861.CrossRefGoogle Scholar
  18. 18.
    Vehar GA, Keyt B, Eaton D, et al. Structure of human factor VIII. Nature. 1984;312:337–342.CrossRefGoogle Scholar
  19. 19.
    Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem. 1988;263:6352–6362.PubMedGoogle Scholar
  20. 20.
    Rehemtulla A, Kaufman RJ. Protein processing within the secretory pathway. Curr Opin Biotechnol. 1992;3:560–565.CrossRefGoogle Scholar
  21. 21.
    Precup JW, Kline BC, Fass DN. A monoclonal antibody to factor VIII inhibits von Willebrand factor binding and thrombin cleavage. Blood. 1991;77:1929–1936.PubMedGoogle Scholar
  22. 22.
    Handin RI, Wagner DD. Molecular and cellular biology of von Willebrand factor. Prog Hemost Thromb. 1989;9:233–259.PubMedGoogle Scholar
  23. 23.
    Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505–512.CrossRefGoogle Scholar
  24. 24.
    O’Brien DP, Johnson D, Byfield P, Tuddenham EG. Inactivation of factor VIII by factor IXa. Biochemistry. 1992;31:2805–2812.CrossRefGoogle Scholar
  25. 25.
    Fay PJ, Smudzin TM, Walker FJ. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa: identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem. 1991;266:20139–20145.PubMedGoogle Scholar
  26. 26.
    Oldenburg J, Ananyeva NM, Saenko EL. Molecular basis of haemophilia A. Haemophilia. 2004;10:133–139.CrossRefGoogle Scholar
  27. 27.
    El-Maarri O, Olek A, Balaban B, et al. Methylation levels at selected CpG sites in the factor VIII and FGFR3 genes, in mature female and male germ cells: implications for male-driven evolution. Am J Hum Genet. 1998;63:1001–1008.CrossRefGoogle Scholar
  28. 28.
    Millar DS, Krawczak M, Cooper DN. Variation of site-specific methylation patterns in the factor VIII (F8C) gene in human sperm DNA. Hum Genet. 1998;103:228–233.CrossRefGoogle Scholar
  29. 29.
    Zhang B, Ginsburg D. Familial multiple coagulation factor deficiencies: new biologic insight from rare genetic bleeding disorders. J Thromb Haemost. 2004;2:1564–1572.CrossRefGoogle Scholar
  30. 30.
    Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem. 1987;262:8443–8446.PubMedGoogle Scholar
  31. 31.
    El-Maarri O, Herbiniaux U, Graw J, et al. Analysis of mRNA in hemophilia A patients with undetectable mutations reveals normal splicing in the factor VIII gene. J Thromb Haemost. 2005;3:332–339.CrossRefGoogle Scholar
  32. 32.
    El-Maarri O, Singer H, Klein C, et al. Lack of F8 mRNA: a novel mechanism leading to hemophilia A. Blood. 2005. In press.Google Scholar
  33. 33.
    Oldenburg J, El-Maarri O, Schwaab R. Inhibitor development in correlation to factor VIII genotypes. Haemophilia. 2002;8:23–29.CrossRefGoogle Scholar
  34. 34.
    Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74:1402–1406.PubMedGoogle Scholar
  35. 35.
    Oldenburg J, Schroder J, Hermann Brackmann H, Muller-Reible C, Schwaab R, Tuddenham E. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41: 82–88.CrossRefGoogle Scholar
  36. 36.
    Astermark J, Berntorp E, White GC, Kroner BL, and the MIBS Study Group. The Malmü International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7:267–272.CrossRefGoogle Scholar
  37. 37.
    Astermark J, Oldenburg J, Escobar M, White GC 2nd, Berntorp E. The Malmü International Brother Study (MIBS): genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica. 2005;90:924–931.PubMedGoogle Scholar
  38. 38.
    Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK .Polymorphisms in the IL-10 but not in the IL-1β and IL-4 genes are associated with inhibitor development in patients with hemophilia A.Blood. 2005. In press.Google Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  1. 1.Institute of Experimental Haematology and Transfusion MedicineBonnGermany

Personalised recommendations